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Background: When a new drug is launched onto the market, information about the new manufactured product is
contained in its monograph and evaluation report published by national drug agencies. Health professionals need
to be able to determine rapidly and easily whether the new manufactured product is potentially useful for their
practice. There is therefore a need to identify the best way to group together and visualize the main items of
information describing the nature and potential impact of the new drug. The objective of this study was to identify
these items of information and to bring them together in a model that could serve as the standard for presenting
the main features of new manufactured product.
Methods: We developed a preliminary conceptual model of pharmaceutical innovations, based on the knowledge
of the authors. We then refined this model, using a random sample of 40 new manufactured drugs recently
approved by the national drug regulatory authorities in France and covering a broad spectrum of innovations and
therapeutic areas. Finally, we used another sample of 20 new manufactured drugs to determine whether the model
was sufficiently comprehensive.
Results: The results of our modeling led to three sub models described as conceptual maps representingi) the
medical context for use of the new drug (indications, type of effect, therapeutical arsenal for the same indications),
ii) the nature of the novelty of the new drug (new molecule, new mechanism of action, new combination, new
dosage, etc.), and iii) the impact of the drug in terms of efficacy, safety and ease of use, compared with other drugs
with the same indications.
Conclusions: Our model can help to standardize information about new drugs released onto the market. It is
potentially useful to the pharmaceutical industry, medical journals, editors of drug databases and medical software,
and national or international drug regulation agencies, as a means of describing the main properties of new
pharmaceutical products. It could also used as a guide for the writing of comprehensive and objective texts
summarizing the nature and interest of new manufactured product.Background
When a new drug or a new presentation of a drug is mar-
keted, physicians need to be able to determine whether it is
likely to be more useful for the treatment of their patients
than the alternatives already available, and whether it is
likely to modify their treatment practices. It is difficult for
physicians to form their own opinions about a new drug.
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reproduction in any medium, provided the orAnalyses of the official information about a new manufac-
tured product would require considerable effort. This in-
formation is contained in different types of documents: (i)
the summary of product characteristics (SPC), which forms
the basis of its monograph, (ii) the SPCs of other drugs
currently used for the same indication, (iii) the evaluation
report for the new drug published by the national drug
agencies.
Monographs have a standardized structure that varies
little between countries. They include sections on compo-
sition, route of administration, indications, contraindica-
tions, adverse reactions, treatment regimens, etc. However,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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clearly in the monograph, and the monograph alone pro-
vides no comparison with existing drugs for the same
indications. Drug monographs provide sufficient informa-
tion for the safe prescription of a given drug, but too little
information to allow a physician to develop a therapeutic
strategy.
When evaluating a new manufactured product with re-
spect to existing treatments, physicians must first identify
the set of drugs used for a given indication, and then study
the monographs for each drug in the set, section by section,
comparing the properties of each drug with those of the
new drug. This process is time-consuming and unrealistic.
The national and international drug agencies (EMA [1],
ANSM [2], HAS [3], FDA [4]) publish evaluation reports
for each new manufactured product. These reports usually
contain a comparison of the new drug with other drugs
with same indications, recommendations for approval,
and an overview of the clinical program, efficacy data,
safety findings, recommended doses, and information for
use in specific populations. These reports often conclude
with a nation-specific drug-novelty index (e.g. in France,
the Actual Benefit of the drug), which classifies the
innovation as major, important or minor.
Very few physicians read these evaluation reports be-
cause they tend to be long and time-consuming to read.
They also tend to focus on comparisons of the efficacy of
the new manufactured product with other drugs for a
given indication; aspects relating to safety or ease of use
are described in less detail and may even be completely
ignored. Improvements in drug labelling have been pro-
posed, to provide patients and physicians with better
information, including the results of studies comparing
effectiveness [5]. Other authors [6] have highlighted pro-
blems due to a lack of information concerning the value
of the innovation brought by the new drug after entry into
the market. The effectiveness of drug fact boxes for com-
municating information about the benefits and adverse
effects of drugs has been evaluated experimentally. The
results obtained were encouraging, but this approach es-
sentially targets patients and not physicians [7]. A com-
prehensive, but easy to read description of the various
aspects of pharmaceutical innovation is required. There is
therefore a need to develop new tools enabling physicians
and other health professionals to comprehend the main
characteristics and clinical impact of a new manufactured
product both rapidly and easily. This requires the selection
and structuring of the elementary pieces of information
for each pharmaceutical innovation to be provided to the
physician.
The objective of this study was to identify these pieces
of information and to build and validate a conceptual
model including the essential aspects of a new drug to be
presented to physicians.We describe the methods used for the selection and
modeling of information about new drugs and provide
conceptual maps defining the final model.
Methods
Overall approach
We constructed a preliminary conceptual model of phar-
maceutical innovations based on the knowledge of two of
the authors of this paper, CD and AV, who are experienced
in the field of drug-information modeling [8-14]. We then
refined this model, using a random sample of 40 new
manufactured products that had recently been approved
by the national drug authorities in France. We analyzed
the French drug agency reports and SPCs of these drugs,
together with those of other drugs for the same indication,
with which they were to be compared. Finally, we used an-
other sample of 20 new manufactured products from the
same source to determine whether the model was suffi-
ciently comprehensive.
Choice of drugs used to design the model
We studied firstly the evaluation reports for 40 drugs from
a list of 170 drugs that had been approved by the French
National Medicines Assessment Committee between
January 2008 and January 2011. These drugs are presented
in Additional file 1. They were randomly selected, but tak-
ing into account the total number of new products in each
medical discipline and the nature of the pharmaceutical
innovation indicated in the heading of the evaluation re-
port. In this way, we were able to obtain a sample of drugs
with innovations of different natures (new molecule, new
combination, new pharmaceutical form, etc.) for use in di-
verse medical specialties (e.g. cardiology, endocrinology).
We excluded vaccines, which are developed by biological
engineering techniques and cannot be described in the
same way, and drugs for diagnostic purposes, which are
used almost exclusively by radiologists.
We then use another random sample of 20 drugs from
the list of 170 new drugs approved by the French drug au-
thorities between January 2008 and January 2011. These
drugs are presented in Additional file 2. They were used
to investigate whether the principal innovative features of
these drugs could be described with the model.
Designing a model of pharmaceutical innovation
Step 1Two of the authors of this paper, AV and CD
worked together to select an initial set of innovation axes.
For each axis, they proposed a set of items corresponding
to important information for a physician who wants to
know whether a new drug can be useful for his daily
practice.
Step 2Then author MI completed gradually the model
by reading the content of (i) the evaluation reports edited
by experts of Transparency Committee of the French
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products, (ii) the SPCs, validated by the French Agency
for the Safety of Medicine and Health Products for each
new drug. Likewise she used the SPCs of the drugs to
which the new drug is compared in the evaluation report
for the items of the impact and the SPCs of all the drugs
of the therapeutic arsenal for the items of the novelty.
When she identified innovative features which could not
be represented by the model, she suggested to add new
items to the model. Her suggestions were then validated
or not by authors AV and CD working together.
The evaluation reports contain information about
pharmaceutical, toxicological, pharmacological and clin-
ical data concerning efficacy and tolerance, including the
risk/benefit ratio of the product. These reports also in-
clude information about the type of innovation (e.g. a new
combination of drugs, a new formulation or a new dose).
The SPCs were available from drug databases [15-17].
They were used to compare various properties of the new
drug with those of therapeutic arsenalpharmacological
class, pharmacodynamics, contraindications, precautions,
adverse reactions, dosage and administration, overdosage.
We chose to represent the information about pharma-
ceutical innovation with concept maps, which are used to
represent knowledge models [18], particularly in the build-
ing of ontologies [19]. The graphical representation of
these concept maps was generated with FreeMind soft-
ware [20]. It should be stressed that, for drugs with mul-
tiple indications, a concept map must be built for each
indication. For drugs for which no direct comparison stud-
ies were available, we relied on the conclusions of the
experts from national drug regulation agencies.
Analysis of the completeness of the model
The objective was to verify that all the features import-
ant to describe the innovation of a new pharmaceutical
product are covered by the model.
For each of the 20 drugs of the analysis set of the com-
pleteness of the model, their evaluation reports and the
SPCs were analyzed using the same methodology as in
the model development. The objective was to see if the
model was adequate to represent all the information
related to innovation or if new items should be added.Results
Three axes for describing a pharmaceutical innovation
We suggest that new pharmaceutical products should be
described in terms of:
 The context of use of the new product. The medical
problem for which this product is proposed should
be described, together with the various existing
drugs already used for this medical problem. The novelty of the new product. Various aspects
should be considered, including chemical,
pharmacological and pharmaceutical aspects.
 The impact of the new product. The impact of the
new drug, in terms of its efficacy, safety and ease of
use with respect to other drugs of the therapeutic
arsenal should be described separately.
Modeling the medical context of use of the new
manufactured product
The model of the medical context is presented in
figure 1.
Therapeutic innovation can be defined as a new thera-
peutic option to treat a health problem for which there
may already be an existing therapeutic arsenal. The treat-
ment may target a disease, a symptom or a risk factor.
According to the effects of the drug, there are different
types of treatment:
– Curative; the drug eliminates the cause of the
disease (e.g. antibiotics).
– Symptomatic; the drug relieves symptoms arising
from a pathological condition (e.g. analgesics).
– Substitutive; the drug replaces a deficient natural
constituent in the organism (e.g. insulin for
diabetics).
– Preventive; the drug is administered to healthy
subjects as a preventative measure against future
disease or to temporarily modify a physiological
process (e.g. contraceptives).
Additional file 3 gives for each item of context of use,
information sources where its value can be found for a
given drug.
The exact indications and conditions of use of the drug
are specified on the drug label. The therapeutic arsenal for
a particular condition consists of all the drugs for that
indication. These drugs may or may not belong to the
same pharmacotherapeutic group. Figure 2 shows the
concept map built for EfientW (prasugrel hydrochloride,
10 mg, film-coated tablets). EfientW 10 mg (prasugrel) co-
administered with acetylsalicylic acid is indicated for the
prevention of atherothrombotic events in patients with
acute coronary syndrome (i.e. unstable angina, non-ST
segment elevation myocardial infarction [UA/NSTEMI] or
ST segment elevation myocardial infarction [STEMI])
undergoing primary or delayed percutaneous coronary
intervention (PCI).
Modeling the novelty of the new commercial product
Figure 3 presents the various possible aspects of novelty
for a new manufactured product. The nature of the
innovation differs between drugs, which may be new
molecules with or without a new mechanism of action
Figure 1 Concept map portraying the medical context of use of the new manufactured product.
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The innovative aspect may be a new combination of mole-
cules, a known combination in a new form, a new proto-
col, a new dosage form, or a new presentation. The new
manufactured product may incorporate only known mole-
cules, but with new characteristics.
Additional file 4 gives for each item of novelty, informa-
tion sources where its value can be found for a given drug.
The novelty may be due to a new route of administra-
tion, or a new pharmacological form, presentation, dose
or protocol. The route of administration may be novel for
an already existing molecule or related to the mechanism
of action. For new molecules, the route of administration
may be novel with respect to the whole therapeutic
arsenal.
The pharmacological form may be novel for the mol-
ecule, route of administration or relative to the other
drugs used for the same indication.
A new presentation of a drug may also be considered as
a novelty. For example, EpipenW auto-injector, in a single
dose of 0.15 mg epinephrine injection/0.3 ml sterile solu-
tion, is a drug with a new presentation of a known mo-
lecule (epinephrine). The novelty of the drug lies in the
model of injector.Figure 2 Concept map portraying the medical context of use of Efien
prevention of atherothrombotic events. The specific elements of the neThe 40 new drugs chosen included 11 new molecules,
eight of which had a novel mechanism of action and
belonged to a new pharmacotherapeutic group. Five drugs
corresponded to new combinations. There were 24 drugs
corresponding to known molecules, 10 of which had new
features (new form, new route of administration, new
presentation or new dosage) and 14 of which had a new
indication or an extension of the previous indication.
An example is given in Figure 4 for the novelty of
EfientW.
Modeling the impact of the drug
The new manufactured product must be positioned rela-
tive to the set of drug treatments sharing the same
indication.
Figure 5 shows the various elements influencing the im-
pact of the new manufactured product with respect to a
comparator. Additional file 5 gives for each item, informa-
tion sources where its value can be found for a given drug.
Impact on efficacy
A new manufactured product may have an impact on efficacy
through effects on the course of the disease (cure, stabilization
or remission of the disease), on the symptomatology of thetW (prasugrel hydrochloride 10 mg, film coated tablets) for the
w product are shown in blue.
Figure 3 Various possible aspects of novelty for new manufactured product.
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blood pressure), or by preventing the occurrence of the disease
or its complications. The new drug may have no impact on
efficacy.
Impact on safety
The basic characteristics of a drug likely to affect its
safety include adverse reactions, contraindications, drug
interactions and the risk of overdose.
We considered each of the serious adverse reactions
listed in the SPC of the new product and in the ones of
the comparator, determining whether or not it wasFigure 4 Aspects of novelty for EfientW (prasugrel hydrochloride 10 m
shown in blue.present in both lists. A “serious adverse reaction” was
well defined in a previous study [21] and on the website
of the FDA [22].
We also considered contraindications, determining
whether they were present or absent for the new product
and the drugs with which it was being compared.
We also compared the serious drug-drug interactions,
as defined in previous studies [23,24], listed in the SPC of
the new product with those listed in the SPCs of the drugs
with which it was being compared.
Another important characteristic affecting safety is the
risk of drug overdose, which can be very dangerous andg, filmcoated tablets). The specific elements of the new product are
Figure 5 Impact of a new manufactured product with respect to a comparator.
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an antidote.
Finally, the new product may have no impact on safety,
particularly if it contains a known molecule.
Impact on the ease of use
The elements with a potential impact on the ease of use of
drugs by patients or physicians are represented in Figure 5
and must be compared between the new product and
other drugs with the same indication.
For the patient, the number of drug units, the frequency
and duration of administration, the convenience of admin-
istration and its invasiveness may all influence compliance
with the treatment.
For physicians, innovations may lead to treatments that
are easier to monitor (e.gcpe enoxaparin requires more
monitoring tests than rivaroxaban), doses easier to adjust.
Figure 6 shows the impact of EfientW with respect to
PlavixW (clopidogrel, 75 mg, tablet).
Analysis of the completeness of the model
Six of the drugs selected for analysis of the completeness
of model corresponded to new molecules; among them 5
had a new mechanism of action and belonged to a new
pharmacotherapeutic group. Three drugs corresponded to
new combinations and 2 to a known combination with
new dosage.
Nine drugs corresponded to known moleculesthree with
new features and six with a new indication. Two of the six
drugs with new indications had a new mechanism ofaction and belonged to a new pharmacotherapeutic group
for this new indication.
This analysis led to adding only one element to the
model. It is the “the duration of administration” which
concerns the impact on the ease of use of the treatment.
This extra element was minor and did not change the
overall structure of the concept maps.Discussion and conclusion
In this study, we identified the key items of information
required for a fair appraisal of pharmaceutical innovations.
The information concerning a new pharmaceutical prod-
uct was separated into three categoriesi) medical context
of use, including the therapeutic arsenal with same indica-
tion; ii) description of the pharmaceutical characteristics
of the innovation and iii) the expected impact of the new
product in terms of efficacy, safety, and ease of use for the
patient and the physician, as determined by comparison
with other products with the same indication.
We used concept maps to represent the various cha-
racteristics of pharmaceutical innovation. Other methods
could have been used, such as the Unified Modeling
Language, but concept maps have the advantage of being
easy to understand for non modeling specialists [25].
Our model is based on the knowledge of two experts in
the representation of drug information [8-14], as well as
on the analysis of the information for 60 recently
approved new drugs, covering a broad spectrum in terms
of novelty and therapeutic use.
Figure 6 Impact of EfientW (prasugrel hydrochloride 10 mg, film coated tablets) with respect to PlavixW (clopidogrel 75 mg, tablet). A
positive impact of the drug with respect to the comparator is shown in green; an equivalent impact is shown in yellow and a negative impact in red.
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modifications or additions for the representation of other
drugs in the future.
We did not consider the cost-effectiveness of a new
pharmaceutical product in our approach, because this is
influenced by healthcare policy, which may differ from
one country to another.
For each item we have specified the sources of informa-
tion where can be found its value so that it becomes easy
to build the concept maps of a new drug. But our model
raises a key question. If we wish to apply this model to a
new product, do we need expert opinion from specialists
in the medical field corresponding to the drug indication,
or can less specialized pharmacologists do the job? All the
items related to the first two axes can easily be obtained,
with no ambiguity, by reading the evaluation reports of
national or international drug agencies and the SPCs of
the new products and of the products with which they are
compared. For the third axis, related to the impact of the
new drug, a pharmacologist reading the same documents
should be able to apply the model in most cases. However,
in some cases, the conclusions of the pharmacologist con-
cerning the impact of the new product in terms of efficacy
would need to be checked by experts if the results of the
clinical trials described in the evaluation reports are not
sufficiently demonstrative. This point will have to be stud-
ied in the future.It would also be of interest to submit this model to phy-
sicians for evaluation, to eventually obtain suggestions for
new items that may have been omitted in this study.
Another difficulty that may be encountered in the use of
this model is a lack of comparative studies for several
drugs. This may make it difficult to draw firm conclusions
about the impact of the drug. In such cases, the concep-
tual maps will need to be updated when data relating to
efficacy and rare adverse reactions become available.
Our model may have various potential applications. It
allows to clearly identify the questions to be addressed by
someone willing to present a pharmaceutical innovation.
It is therefore potentially very useful to the pharmaceutical
industry as a guide for the writing of comprehensive, ob-
jective texts summarizing the nature and value of new
products. It could also be used by national or international
drug agencies during the evaluation of new products and
could help to standardize the writing of evaluation reports
for new drugs.
Medical journals and drug-database editors could use
this model to summarize the main properties of new and
old pharmaceutical products for prescription. Medical
software editors could develop interactive user interfaces
based on this model, with the aim of presenting the prop-
erties of the new pharmaceutical product to physicians.
We are currently working on developing a prototype of
such software for pharmaceutical innovation visualization.
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